About

**EXPERT INTELLIGENCE PROFILE: Nancy Ostrove, Ph.D.** Dr. Nancy Ostrove presents a significant intelligence gap with limited discoverable credentials, institutional affiliation, or specialty area on record despite her Texas-based practice. Her sole documented litigation experience centers exclusively on pharmaceutical product liability, specifically appearing in Villarreal v. Taro Pharmaceuticals in the Southern District of Texas in 2017. The case data shows three separate entries for the same matter, suggesting either multiple phases of testimony or clerical duplication in court records. Without accessible background information, her methodology, academic credentials, and specific area of expertise within pharmaceutical litigation remain unknown—a potential red flag for both retention and opposition research. From a strategic perspective, Ostrove's 100% plaintiff-side alignment in pharmaceutical cases suggests reliability for plaintiff counsel, but her extremely limited case portfolio raises questions about litigation experience and courtroom presence. The absence of any Daubert challenges may indicate either unremarkable testimony that flew under the radar or insufficient defense scrutiny rather than bulletproof expertise. For plaintiff attorneys, the lack of discoverable credentials presents a high Daubert vulnerability risk, particularly against sophisticated pharmaceutical defense teams who will aggressively challenge expert qualifications. Opposition counsel should immediately probe her educational background, publication history, and the specific nature of her Taro Pharmaceuticals testimony. Without more robust intelligence on her expertise and track record, Ostrove represents a high-risk retention for complex pharmaceutical litigation where expert credibility is paramount.

Daubert Record 0 on record

No Daubert challenges on record.

Case Appearances from PACER filings